RecruitingNCT07255638

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany

A Prospective Non-Interventional Study to Describe the Effectiveness of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis and Symptoms That Are Not Adequately Controlled With Symptomatic Treatments in Real-World Settings

Sponsor

Blueprint Medicines Corporation

Enrollment

80 participants

Start Date

Dec 9, 2025

Study Type

OBSERVATIONAL

Conditions

Indolent Systemic Mastocytosis

Summary

This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data gap in the natural history and management of participants with ISM. The study is designed to follow each participant up to a maximum of 24 months.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Avapritinib for people with indolent systemic mastocytosis. The study is currently recruiting participants at 8 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAvapritinib

Avapritinib will be administered as an oral tablet.

Locations(8)

Charité Universitätmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie

Berlin, Germany

Katholisches Klinikum Bochum

Bochum, Germany

MVZ Klinikum Deggendorf

Deggendorf, Germany

Universitätsklinikum Carl Gustav Carus Dresden Klinik und Poliklinik für Dermatologie

Dresden, Germany

University Medical Center Goettingen - Georg August University of Goettingen

Göttingen, Germany

Universitats-Hautklinik Tubingen, Studienzentrum lmmundermatologie

Tübingen, Germany

HNO-Gemeinschaftspraxis Wiesbaden, GEKA Gesellschaft für Experimentelle und Klinische Atemwegsforschung mbH, Zentrum für Rhinologie und Allergologie

Wiesbaden, Germany

Helios Universitätsklinikum Wuppertal

Wuppertal, Germany

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07255638

Related Trials

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

NCT0491068571 locations

An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)

NCT072649591 location

Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis

NCT0465511852 locations